- Home
- ANL vs RENB Comparison
ANL vs RENB Comparison
Compare ANL & RENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANL
- RENB
- Stock Information
- Founded
- ANL 2004
- RENB 2011
- Country
- ANL Cayman Islands
- RENB United States
- Employees
- ANL N/A
- RENB N/A
- Industry
- ANL
- RENB Biotechnology: Pharmaceutical Preparations
- Sector
- ANL
- RENB Health Care
- Exchange
- ANL Nasdaq
- RENB Nasdaq
- Market Cap
- ANL 56.0M
- RENB 57.7M
- IPO Year
- ANL 2023
- RENB N/A
- Fundamental
- Price
- ANL $1.45
- RENB $0.26
- Analyst Decision
- ANL Hold
- RENB
- Analyst Count
- ANL 1
- RENB 0
- Target Price
- ANL N/A
- RENB N/A
- AVG Volume (30 Days)
- ANL 6.9K
- RENB 1.4M
- Earning Date
- ANL 08-12-2025
- RENB 05-15-2025
- Dividend Yield
- ANL N/A
- RENB N/A
- EPS Growth
- ANL N/A
- RENB N/A
- EPS
- ANL N/A
- RENB N/A
- Revenue
- ANL N/A
- RENB N/A
- Revenue This Year
- ANL N/A
- RENB N/A
- Revenue Next Year
- ANL N/A
- RENB N/A
- P/E Ratio
- ANL N/A
- RENB N/A
- Revenue Growth
- ANL N/A
- RENB N/A
- 52 Week Low
- ANL $1.10
- RENB $0.25
- 52 Week High
- ANL $3.89
- RENB $2.10
- Technical
- Relative Strength Index (RSI)
- ANL 44.72
- RENB 38.45
- Support Level
- ANL $1.48
- RENB $0.30
- Resistance Level
- ANL $1.55
- RENB $0.35
- Average True Range (ATR)
- ANL 0.04
- RENB 0.03
- MACD
- ANL -0.00
- RENB -0.00
- Stochastic Oscillator
- ANL 25.00
- RENB 7.22
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About RENB Renovaro Biosciences Inc.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.